These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 31960124)
1. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Banna GL; Urzia V; Benanti C; Pitrè A; Lipari H; Di Quattro R; De Giorgi U; Schepisi G; Basso U; Bimbatti D; Rundo F; Libra M; Malatino L Support Care Cancer; 2020 Oct; 28(10):4687-4695. PubMed ID: 31960124 [TBL] [Abstract][Full Text] [Related]
2. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393 [TBL] [Abstract][Full Text] [Related]
3. Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide. Riekhof F; Yan Y; Bennett CL; Sanfilippo KM; Carson KR; Chang SH; Georgantopoulos P; Luo S; Govindan S; Cheranda N; Afzal A; Schoen MW Clin Genitourin Cancer; 2024 Apr; 22(2):18-26.e3. PubMed ID: 37495480 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study. Zhang L; Zhou L; Shi Y; An X Asian J Surg; 2024 Aug; 47(8):3577-3578. PubMed ID: 38644125 [No Abstract] [Full Text] [Related]
5. Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer. Baker A; Syed A; Mohany M; Elgorban AM; Sajid Khan M; Al-Rejaie SS Eur J Pharm Biopharm; 2023 Nov; 192():88-111. PubMed ID: 37797680 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report. Pokrivcak T; Navratil J; Poprach A; Stanik M; Kiss I Case Rep Oncol; 2024; 17(1):537-542. PubMed ID: 38577248 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model. Merdita S; Šíma M; Dvořák J; Matějů M; Richter I; Kozlík P; Křížek T; Královičová J; Bosák J; Petruželka L; Slanař O Br J Clin Pharmacol; 2024 Oct; 90(10):2652-2662. PubMed ID: 38958217 [TBL] [Abstract][Full Text] [Related]
8. Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. Suttmann H; Gleissner J; Huebner A; Mathes T; Baurecht W; Krützfeldt K; Sweiti H; Feyerabend S Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32911627 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan. Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973 [TBL] [Abstract][Full Text] [Related]
10. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985 [TBL] [Abstract][Full Text] [Related]
11. Exploring Spatial-Temporal Changes in Kyriakopoulos CE; Heath EI; Ferrari A; Sperger JM; Singh A; Perlman SB; Roth AR; Perk TG; Modelska K; Porcari A; Duggan W; Lang JM; Jeraj R; Liu G J Clin Oncol; 2020 Nov; 38(31):3662-3671. PubMed ID: 32897830 [TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Banna GL; Di Quattro R; Malatino L; Fornarini G; Addeo A; Maruzzo M; Urzia V; Rundo F; Lipari H; De Giorgi U; Basso U Clin Transl Oncol; 2020 Nov; 22(11):2130-2135. PubMed ID: 32232716 [TBL] [Abstract][Full Text] [Related]
13. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489 [TBL] [Abstract][Full Text] [Related]
14. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427 [TBL] [Abstract][Full Text] [Related]
15. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096 [TBL] [Abstract][Full Text] [Related]